Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China

Xiao-chun He, Ning-ning Tao, Yao Liu, Xian-xin Zhang and Huai-chen Li

Abstract

Background: Extensively Drug-Resistant (XDR) Tuberculosis (TB) has posed a great threat to global health and finance systems, especially for developing countries with high TB and Multidrug-Resistant (MDR) TB burden.

Methods: We retrospectively analyzed HIV-uninfected TB case confirmed and treated in Shandong Provincial Chest Hospital (SPCH) between January 2008 and December 2015. Unique characteristics of XDR-TB were identified; its longitudinal changes and survival were analyzed.

Results: Between January 2008 and December 2015, a total of 144 cases were confirmed to be XDR-TB (2.5% of 5663 culture-confirmed TB cases; 27.9% of 516 MDR-TB cases). The proportion of XDR TB cases among MDR-TB cases has increased from 26.5% in 2008 to 44.5% in 2014 (Chi-Square test for trends: P < 0.01). Among the 144 XDR-TB cases, 21 patients (14.6%) had treatment success, 123 (85.1%) had poor treatment outcomes. Mortality was higher among XDR-TB cases than among MDR TB cases (8.3% vs. 3.8%, P = 0.033) and drug-susceptible TB cases (8.3% vs. 2.1%, P < 0.01).

Conclusions: XDR-TB cases comprise a substantial and increasing fraction of MDR-TB cases, causing poor treatment outcomes and high mortalities. Early drug susceptibility testing, adequate TB treatment and efficient infection control must be in place in future TB control strategies.

Keywords: XDR-TB, Epidemiology trends, Treatment outcomes, Survival

Background

Extensively drug-resistant tuberculosis (XDR-TB), which is defined as tuberculosis resistant to isoniazid, rifampin, a fluoroquinolone, and a second-line injectable agent, has posed a great threat to global public health [1–3]. XDR TB is a subset of multidrug-resistant (MDR) TB, which is resistant to both isoniazid and rifampin [4]. Rooted in inappropriate TB treatment [5–8] and compounded by the neglect of airborne infection control [9, 10], the emergence and spread of XDR-TB worldwide reflect the weakness in global TB management. XDR-TB puts TB patients in a predicament with limited therapeutic options that are more toxic, more costly, and less effective and consequently have poorer treatment outcomes and higher mortality [11–14].

In 2014, an estimated 650,000 (5.4%) of the world’s 12 million prevalent cases of TB had MDR-TB. According to WHO, about 9.7% of people with MDR-TB have XDR-TB. The proportion of XDR-TB among MDR-TB cases was highest in Belarus (29%), Georgia (15%), Latvia (19%) and Lithuania (25%) [15]. China is a country of high TB and MDR-TB burden and a countrywide survey in 2007 revealed that the proportion of XDR-TB among MDR-TB cases was 8% [15, 16]. Nevertheless, XDR TB is probably an underestimated problem in mainland China; recent studies [17–19] suggested that the proportion of XDR-TB may be substantially higher than previously reported. However, systematic data on the epidemiology of XDR-TB remain limited, and most reports focus on populations from special surveys or go through short time intervals, information such as longitudinal changes...
and survival analysis has not yet been reported in mainland China.

This study was based on clinical information collected from the only provincial TB specialized hospital in Shandong province. We aimed to determine XDR-TB burden more accurately by considering all reported drug susceptibility test results for case counting and by analyzing secular trends across an 8-year study period. To identify specific characteristics of XDR-TB, we compared the basic characteristics and survival of XDR-TB cases with both MDR-TB and drug-susceptible TB cases.

Methods
Ethics statement
The study was approved by the Ethic Committee of Shandong Provincial Hospital, affiliated to Shandong University. Patient records were anonymized and de-identified prior to analysis.

Study population and data collection
Shandong province lies in the east coast of China and is the second largest province with a population of 95 million. In 2013, 35,971 people in Shandong were infected with latent TB. Shandong Provincial Chest Hospital (SPCH) is the only provincial-level hospital specializing in TB clinical service and control. This retrospective study enrolled consecutive human immunodeficiency virus (HIV)-uninfected culture-positive Mycobacterium tuberculosis cases confirmed and treated in SPCH between January 2008 and December 2015. Trained research clinicians reviewed the medical records of these TB patients and abstracted their drug susceptibility test (DST) results along with the corresponding sociodemographic and clinical information using a standard case report form.

Drug susceptibility testing
All the enrolled TB patients had DST results for first line antituberculosis drugs isoniazid, rifampin, ethambutol, streptomycin, and, for at least 1 fluoroquinolone (ofloxacin, levofloxacin, ciprofloxacin) and 1 injectable agent (capreomycin, kanamycin, amikacin).

DST was performed using the proportion method with Löwenstein–Jensen (L-J) medium. The critical concentrations for resistance were as follows [20]: isoniazid (0.2 μg/mL), rifampicin (40 μg/mL), ethambutol (2.0 μg/mL), streptomycin (4.0 μg/mL), ofloxacin (2.0 μg/mL), levofloxacin (1.0 μg/mL), ciprofloxacin (2.0 μg/mL), capreomycin (40 μg/mL), kanamycin (30 μg/mL), amikacin (10 μg/mL) and para-aminosalicylic (1.0 μg/mL). External quality assessment was conducted regularly by TB National Reference Laboratory.

Definitions
New TB cases were defined as TB patients who had never been treated for TB or had taken anti-TB drugs for less than 1 month. Previously treated TB cases were those who had been receiving TB treatment for at least 1 month. A drug-susceptible TB case was defined as an individual susceptible to isoniazid and rifampin in both initial and follow-up DST results. An MDR-TB case was defined as a person resistant to at least isoniazid and rifampin. MDR-TB cases that had additional resistance to a fluoroquinolone and a second line injectable drug were defined as XDR-TB cases.

Treatment outcomes were defined according to the WHO and International Union Against Tuberculosis and Lung Disease (IUATLD) guidelines [21, 22]. “Cured” was defined as one who had completed treatment and had been consistently culturenegative (with at least 5 results) for the final 12 months of TB treatment. Patients who completed treatment but did not meet the definition for cure because of lack of bacteriological results were considered to have “completed treatment”. Patients who did not receive treatment for ≥ 2 consecutive months were defined as having “defaulted treatment”.

“Treatment Failure” was defined as ≥ 2 positive cultures recorded in the final 12 months or if any 1 of the final three cultures was positive. “Transferred out” means anyone who transferred to another institution and for whom the treatment outcome was unknown. “Death” was defined as death during treatment due to any cause. For analysis purposes, “cured” and “completed treatment” were classified as “Treatment Success”, whereas others were classified as “Poor Treatment Outcome”.

Statistical analysis
To identify unique features of XDR-TB, we compared sociodemographic and clinical characteristics of XDR-TB with MDR-TB and drug-susceptible TB, respectively. Categorical variables were compared using Chi-square Test or, when appropriate, Fisher’s exact test; continuous variables were analyzed with use of the Mann-Whitney U test. Chi-Square test for trends and linear regression were used to assess the changes in proportions of XDR-TB over time. Unadjusted survival rates were estimated by the Kaplan-Meier method, and any differences in survival were evaluated with the log-rank test. Multivariate Cox regression models were used to estimate the simultaneous effects of prognostic factors on survival. Death was the event variable and other outcomes were censored. Tests of significance were 2-sided, and a P value <0.05 was considered statistically significant. All analyses were performed by using SPSS software, version 16.0.
Results
Drug resistance patterns

Between January 2008 and December 2015, a total of 5664 culture-confirmed Mycobacterium tuberculosis cases were reported and treated at SPCH. Of these, 1 patient co-infected with HIV was excluded from further analysis. Among the remaining 5663 TB cases, 4622 (81.6%) cases were drug-susceptible. There were 516 (9.1%) cases with resistance to at least isoniazid and rifampin, meeting the case definition for MDR-TB. In our study, all the MDR-TB cases had susceptibilities reported for at least 1 fluoroquinolone and 1 injectable agent, namely, all the MDR-TB cases were XDR-TB evaluable. Ultimately, 144 cases were confirmed to have XDR-TB (2.5% of 5663 culture-confirmed TB cases; 27.9% of 516 MDR-TB cases). We excluded 525 TB cases with other drug resistance patterns from further analysis (Fig. 1).

Treatment histories were available for the whole study cohort. Out of the 5663 TB cases, 4999 (88.3%) were new TB cases and 664 (11.7%) were previously treated TB cases. In new TB cases, the proportions of MDR TB and XDR TB were 4.2% and 1.5%, respectively. While the corresponding proportions were 24.7% and 10.7% in previously treated TB cases.

Trends over time

The annual number of XDR-TB cases has fluctuated around a median of 12 cases per year during our study period, and the proportion of XDR TB cases among MDR TB cases has increased from 26.5% in 2008 to 44.5% in 2014 ($R^2 = 0.311$; Chi-Square test for trends: $\chi^2 = 14.097, P < 0.01$) (Fig. 2). Further breakdown into new- and previously treated-TB cases showed that the proportion of XDR TB cases among MDR TB cases has increased in both 2 groups.

Fig. 1 TB cases in Shandong, China. NTM, nontuberculous mycobacteria; MDR, multi-drug resistant; XDR, extensively drug resistant
From 13.3% in 2008 to 41.1% in 2014 in new TB cases \( (R^2 = 0.74; \chi^2 = 12.894, P < 0.001) \) and from 32.4% in 2008 to 51.4% in previously treated TB cases \( (R^2 = 0.185; \chi^2 = 4.897, P = 0.027) \), respectively.

**Sociodemographic characteristics**

The median age of the 144 XDR-TB patients was 42 years (IQR, 27–59 years), and 88 (61.1%) were males.

When compared to MDR-TB and drug-susceptible TB cases, XDR-TB cases were significantly more likely to be in the older age groups (median age, 42 vs. 30 years, \( P < 0.01 \); 42 vs. 32 years, \( P < 0.01 \), respectively). Moreover, XDR-TB cases were less likely to be in the student group when compared with drug-susceptible TB cases (5.6% vs. 11.4%, \( P = 0.029 \); OR 0.46, 95% CI 0.22–0.94). Other sociodemographic characteristics showed no differences between different groups (Table 1).

**Clinical and treatment characteristics**

Clinical characteristics did not differ between XDR-TB and MDR TB cases (Table 2). However, a previous diagnosis of TB was more than 13 times as likely among XDR-TB cases compared with drug-susceptible TB cases (49.3% vs. 6.5%, \( P < 0.001 \); OR 13.96, 95% CI 9.87–19.75). And XDR-TB cases were more likely to have disseminated disease (ie. pulmonary and extrapulmonary disease) (16% vs. 9.5%, \( P = 0.01 \); OR 1.80, 95% CI 1.14–2.85), had a greater chance to have cavity disease (50.7% vs. 35%, \( P < 0.001 \); OR 1.91, 95% CI 1.37–2.66) and to have...
and anticholinergic agents. In our study, all COPD patients had been diagnosed before TB diagnosis.

Completeness of DOT

Complete DOT refers to TB treatment under direct observation of health workers from hospitals/communities and trained family members; Partial DOT refers to DOT combined with some self-administered therapy.

TB retreatment

TB retreatment means that the case has received TB treatment before the current TB episode for one month or more [20].

Table 2 Clinical and treatment characteristics of extensively drug-resistant tuberculosis (XDR-TB), multidrug-resistant tuberculosis (MDR-TB), and drug-susceptible TB cases, Shandong, China

| Characteristics                        | XDR TB (n = 144) | MDR TB (n = 372) | Drug-susceptible TB (n = 4622) | OR (95% CI)                                                                 |
|----------------------------------------|------------------|------------------|--------------------------------|-----------------------------------------------------------------------------|
| TB contact                             | 10 (6.9)         | 42 (11.3)        | 318 (6.9)                      | 0.59 (0.29–1.20)                                                            |
| TB retreatment                         | 71 (49.3)        | 164 (44.1)       | 301 (6.5)                      | 1.23 (0.84–1.81)                                                            |
| Location of TB disease                 |                  |                  |                                |                                                                             |
| Pulmonary alone                        | 113 (78.5)       | 313 (84.1)       | 3939 (85.2)                    | 0.69 (0.42–1.12)                                                            |
| Extrapulmonary alone                   | 8 (5.6)          | 15 (4.0)         | 242 (5.2)                      | 1 [Reference]                                                              |
| Pulmonary and extrapulmonary           | 23 (16)          | 44 (11.8)        | 441 (9.5)                      | 1.42 (0.82–2.45)                                                            |
| Chest radiograph result                |                  |                  |                                |                                                                             |
| Cavity                                 | 73 (50.7)        | 171 (46.0)       | 1619 (35.0)                    | 1.21 (0.82–1.78)                                                            |
| Bilateral disease                      | 101 (70.1)       | 238 (64.0)       | 2695 (58.3)                    | 1.32 (0.87–2.00)                                                            |
| Comorbidities                          |                  |                  |                                |                                                                             |
| Diabetes                               | 17 (11.8)        | 35 (9.4)         | 521 (11.3)                     | 1.29 (0.70–2.38)                                                            |
| Hypertension                           | 7 (4.9)          | 10 (2.7)         | 269 (5.8)                      | 1.85 (0.69–4.96)                                                            |
| Cardio-cerebrovascular disease         | 6 (4.2)          | 11 (3.0)         | 212 (4.6)                      | 1.43 (0.52–3.93)                                                            |
| COPD*                                  | 7 (4.9)          | 12 (3.2)         | 88 (1.9)                       | 1.53 (0.59–3.97)                                                            |
| Gastric ulcer/Gastrectomy history      | 7 (4.9)          | 9 (2.4)          | 153 (3.3)                      | 2.06 (0.75–5.64)                                                            |
| Hepatitis                              | 3 (2.1)          | 3 (0.8)          | 67 (1.4)                       | 2.62 (0.52–13.12)                                                           |
| Chronic renal failure                  | 1 (0.7)          | 4 (1.1)          | 43 (0.9)                       | 0.64 (0.07–5.81)                                                            |
| Long-term use of corticosteroids       | 3 (2.1)          | 4 (1.1)          | 65 (1.4)                       | 1.96 (0.43–8.86)                                                            |
| Malignancy                             | 2 (1.4)          | 2 (0.5)          | 67 (1.4)                       | 2.61 (0.36–18.68)                                                           |
| Hypoalbuminemia                        | 9 (6.2)          | 27 (7.3)         | 446 (9.6)                      | 0.85 (0.39–1.66)                                                            |
| Hepatotoxicity during treatment        | 18 (12.5)        | 40 (10.8)        | 534 (11.6)                     | 1.19 (0.66–2.15)                                                            |
| DOT                                    |                  |                  |                                |                                                                             |
| Complete DOT†                          | 92 (63.9)        | 308 (82.8)       | 4450 (96.3)                    | 1 [Reference]                                                              |
| Partial DOT                            | 52 (36.1)        | 64 (17.2)        | 172 (3.7)                      | 2.72 (1.76–4.20)                                                            |
| Hospital LOS                           | 78 (45–132)      | 70 (41–103)      | 46 (34–65)                     | 1 [Reference]                                                              |

Abbreviations: No. number, vs versus, OR odds ratio, CI confidence interval, MDR multidrug-resistant, XDR extensively drug-resistant, COPD chronic obstructive pulmonary disease; DOT directly observed therapy, LOS length of stay

*TB contact was defined as family members, schoolmates or colleagues with TB

**TB retreatment means that the case has received TB treatment before the current TB episode for one month or more [20]

*Statistically significant at P < 0.05

**COPD was diagnosed according to the guidelines of Global Initiative for Chronic Obstructive Lung Disease (GOLD). Defined by a post-bronchodilator pulmonary function (forced expired volume in one second (FEV1)/forced vital capacity (FVC) ratio) of less than 70%, with prescription of a combination of various bronchodilators and anticholinergic agents. In our study, all COPD patients had been diagnosed before TB diagnosis

*Complete DOT refers to TB treatment under direct observation of health workers from hospitals/communities and trained family members; Partial DOT refers to DOT combined with some self-administered therapy

bilateral lesions (70.1% vs. 58.3%, P = 0.005; OR 1.68, 95% CI 1.17–2.41) in chest radiology compared to drug-susceptible TB. Of note, XDR-TB cases were more likely to have underlying chronic obstructive pulmonary disease (COPD) (4.9% vs. 1.9%, P = 0.012; OR 2.63, 95% CI 1.20–5.79) when compared to drug-susceptible TB cases.

For treatment characteristics, XDR-TB cases were more likely to have received treatment under partial rather than total directly observed therapy when compared with MDR TB and drug-susceptible TB cases (OR 2.72, 95% CI 1.76–4.20 vs. MDR TB; OR 14.62, 95% CI 10.08–21.23 vs. drug-susceptible TB), and to stay longer in the hospital (median LOS, 78 vs. 70 days, P = 0.025 when compared to MDR TB cases; 78 vs. 46 days, P < 0.001 when compared to drug-susceptible TB cases).

Treatment outcomes

XDR TB patients had significantly worse outcomes than MDR TB and drug susceptible TB cases. We found that patients with XDR TB had a relative risk of 2.33 to die (95% CI, 1.05–5.16; P = 0.033) and of 3.19 to have treatment failure (95% CI, 2.11–4.82; P < 0.001), compared
with patients with MDR TB. And it is even more prominent when compared with drug susceptible TB cases, with a relative risk of 4.24 to die (95% CI, 2.27–7.92; \( P < 0.001 \)) and of 9.96 to have treatment failure (95% CI, 7.05–14.06; \( P < 0.001 \)) (Table 3).

**Survival analysis**

Participants were followed up for a range of 12.3 to 109.4 months (median 45.5; IQR, 29.1–75.9), starting from initiation of treatment to the end of follow-up in September 30, 2016 or to the date of death.

Figure 3 shows Kaplan-Meier estimates of survival based on the number of deaths from any cause among patients with XDR-TB, MDR TB and drug-susceptible TB. Survival was statistically worse among XDR-TB cases compared with both MDR TB cases (\( \chi^2 = 5.806, P = 0.016 \)) and drug-susceptible TB cases (\( \chi^2 = 35.603, P < 0.001 \)) using the log-rank test.

Within one year, 6 XDR-TB cases (5.7%) had died during treatment compared with 4 MDR TB cases (1.6%; \( P = 0.038 \)) and 41 drug-susceptible TB cases (1.2%; \( P = 0.002 \)).

**Discussion**

It is a large population and long term-based retrospective study that provides the first comprehensive assessment of XDR-TB in China and represent 8 years of the surveillance data almost from the first terming of XDR-TB in 2006.

The emergence of XDR-TB globally has raised awareness and concern about incurable forms of TB. Between January 2008 and December 2015, a total of 144 XDR-TB cases were identified, accounting for 27.9% of MDR-TB cases in our sample population, which is way above the average level (9%) globally in 2014 [15]. By contrast, a rate of 6.3%–12.8% has been documented in most of the previous studies from different regions of China, revealing the high prevalence of XDR-TB in our setting [16–18, 23, 24]. However, the rate is quite similar to the 23.59% from 2010 nationwide population-based survey in China [25]. The high prevalence of XDR-TB could be explained by the fact that our study was a provincial TB hospital based surveillance study, with a relatively high proportion of intractable patients. Second, in previous studies, not all of the MDR-TB cases were XDR-TB evaluable and there were less second line drugs included in the DST panel, which may have led to selection bias and underestimation of the XDR TB prevalence.

It is also noteworthy that the proportion of XDR-TB cases among MDR-TB cases increased from 26.5% in 2008 to 44.5% in 2014, increasing at a yearly rate of 2.9% throughout the study period. Separate analysis of new- and previously treated- TB cases showed that the increase of this proportion is due to the increase of XDR-TB proportion in both 2 groups. There have been few reports about the longitudinal changes of XDR-TB in China, the increase of XDR-TB in both new- and previously treated- TB cases in our study is a wake-up call for the inefficiency of existing TB control policies towards XDR-TB.

In our study, the outcomes of XDR-TB cases were poorer than MDR-TB cases just like other studies. The treatment success rates were 14.6% for XDR-TB cases and 44.6% for MDR-TB cases, respectively. And the 14.6% success rate of XDR-TB treatment was much lower than 29.2–60.4% rates in previous studies [11, 26–29]. One of the possible reasons is the relatively high loss-to-follow-up rates in our study. Second, treatment of XDR-TB cost a lot and free second-line TB drugs are not routinely available in China, leading to intermittent or irregular treatment. Third, DST are not routinely performed in many unspecialized hospitals, XDR-TB cannot be found and treated as early as possible, which has a great impact on treatment effectiveness.

Due to the absence of HIV co-infection, mortalities of TB cases in our study are much lower than previous

| Treatment outcomes | NO. (%) | OR (95% CI) |
|--------------------|---------|-------------|
| Treatment outcomes | XDR TB (n = 144) | MDR TB (n = 372) | Drug-susceptible TB (n = 4622) | XDR TB vs MDR TB | XDR TB vs Drug susceptible TB |
| Treatment Success  |                      |                        |                               |                  |                          |
| Cure               | 8 (5.6) | 51 (13.7) | 1719 (37.2) | 0.37 (0.17–0.80)a | 0.10 (0.05–0.20)b |
| Treatment completion| 13 (9) | 115 (30.9) | 1248 (27.0) | 0.22 (0.12–0.41)b | 0.27 (0.15–0.48)b |
| Poor Treatment Outcome |           |                        |                               |                  |                          |
| Death              | 12 (8.3) | 14 (3.8) | 97 (2.1) | 2.33 (1.05–5.16)a | 4.24 (2.27–7.92)b |
| Failure            | 66 (45.8) | 78 (21.0) | 362 (7.8) | 3.19 (2.11–4.82)b | 9.96 (7.05–14.06)b |
| Default            | 6 (4.2) | 12 (3.2) | 91 (2.0) | 1.30 (0.48–3.54) | 2.17 (0.93–5.03) |
| Transfer out/unknown/missing | 39 (27.1) | 102 (27.4) | 1105 (23.9) | 1 [Reference] | 1 [Reference] |

aStatistically significant at \( P < 0.05 \)
bStatistically significant at \( P < 0.001 \)
studies with a relatively high prevalence of HIV infection [3, 8, 13, 30]. But still, the death rates were significantly higher among XDR-TB cases compared with both MDR TB cases and drug-susceptible TB cases in our study, which was in consistent with previous studies [3, 13].

XDR TB and drug-sensitive TB patients have very distinct differences in clinical characteristics. XDR TB cases are more likely to have cavity, bilateral and extrapulmonary disease than drug-sensitive TB cases. It could be closely related to their underlying duration of disease. Due to the belated drug susceptibility testing and their belated results, XDR- and MDR-TB patients often are inappropriately put on first-line therapy which they inevitably fail. Significant time passes before these patients are recognized as having MDR or XDR TB allowing for disease progression. On the other hand, it also have important implications that XDR TB are more likely to be infectious. Cavity is verified to be a symbol of TB infectivity, and a previous study has shown that XDR TB cases have prolonged infectious period of approximately 6 months, underscores the urgent need for improving the prevention, diagnosis, and treatment of XDR-TB [13].

It is not a total surprise that we found XDR-TB cases were more likely to be in the older age groups and to have underlying COPD. COPD is a major public health problem in China, accounting for 8.2% individuals aged >40 years [31], they are usually malnourished or have compromised immunities, potentially increase the chance of active TB infection [32, 33]. In addition, a substantial proportion of COPD patients experience reiterative hospitalization and antibiotic treatment, selection and nosocomial transmission of resistant strains are thus inevitable in these individuals [34–38]. It has been documented that COPD was an independent risk factor associated with fluoroquinolone resistant tuberculosis in a previous study [39]. In the present study, 4.9% of XDR-TB cases were complicated with COPD, which is a relatively high proportion calling for our attention. TB patients with COPD should be noticed and DST for second line drugs should be performed at the very beginning of the disease to identify possible XDR-TB cases, moreover, treatment strategies and optimal duration for XDR-TB patients with underlying COPD remains to be determined.

Limitations of our findings are due to the retrospective study design. Detailed TB treatment histories, genotyping and molecular typing data are not included in case reporting. Though we founded that 45.1% of XDR-TB cases in our study were from primary transmission, the relative importance of primary XDR-TB transmission vs. additional drug resistance during treatment is still undetermined. And possible exogenous reinfection during hospitalization cannot be ruled out.

**Conclusions**

The present study has important implications for TB control efforts in China. The sizable proportion of XDR-TB cases among MDR-TB cases and its increasing trend in both new- and previously treated- TB cases as well as the poor treatment outcomes sounded the alarm about the inefficiency of existing TB control policies towards XDR-TB. Delayed drug susceptibility testing, suboptimal prescriptions and inadequate infection control precautions may have contributed to the development of XDR TB strains in our study population. Lessons learned from
MDR-TB in the 1990s should be applied: efficient infection control, prompt diagnosis, early drug susceptibility testing, adequate TB treatment, and consistent use of directly observed therapy must be in place to prevent further emergence and transmission of XDR-TB in places with similar settings.

Abbreviations
CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; DOT: Directly observed therapy; DR-TB: Drug-resistant tuberculosis; DST: Drug susceptibility testing; FEV1: Forced expired volume in 1 s; FVC: Forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; HIV: Human immunodeficiency virus; IQR: Inter quartile range; IUATLD: The International Union Against Tuberculosis and Lung Disease; LOS: Length of stay; MDR-TB: Multidrug-resistant tuberculosis; NTM: Non-tuberculous mycobacteria; OR: Odds ratio; SPCH: Shandong Provincial Chest Hospital; TB: Tuberculosis; WHO: World Health Organization; XDR-TB: Extensively drug-resistant tuberculosis

Acknowledgments
We thank Dr. Peng-cheng Huai for providing us with statistical consultation.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
LHC conceived the idea for the paper and developed the approach, contributed to the development of the paper, and commented on and approved the final version. HXC helped to conceive the study, designed and performed the experiments, analyzed the data, drafted the paper, and commented on and approved the final version. LY contributed to the development of the paper, and commented on and approved the final version. TNN and ZXK made substantial contributions to the acquisition and collection of data; helped to analyze the data and gave final approval of the version to be published.

Ethics approval and consent to participate
The study was approved by the Ethic Committee of Shandong Provincial Hospital, affiliated to Shandong University (approval number: 2016–0022).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Respiratory Medicine, Baoji Central Hospital, Baoji, Shaanxi, China. 2Department of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China. 3Department of Respiratory Medicine, Shandong Provincial Chest Hospital, Jinan, Shandong, China.

References
1. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13:380–7.
2. Raviglione MC, Smith IM. XDR tuberculosis—implications for global public health. N Engl J Med. 2007;356:656–9.
3. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1573–80.
4. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000–2004. MMWR Morb Mortal Wkly Rep. 2006;55:301–5.
5. Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM1/ KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis. 2007;45:1409–14.
6. Jeon CY, Hwang SH, Min JH, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008;46:492–9.
7. Cegielski JP, Dalton T, Yagiu M, et al. Extensive drug resistant acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59:1049–63.
8. Dheda K, Shan K, Zumbal A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798–807.
9. O’Donnell MR, Jarad J, Loveday M, et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med. 2010;153:516–22.
10. Gandhi NR, Weissman D, Moodley P, et al. Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa. J Infect Dis. 2013;207:9–17.
11. Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45:1290–5.
12. Migliori GB, Lange C, Centris R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J. 2008;31:1155–9.
13. Shah NS, Pratt R, Armstrong L, Robson-V, Castro KG, Cegielski JP. Extended Drug-Resistant Tuberculosis in the United States, 1993–2007. JAMA. 2008;300:2153–60.
14. Marks UM, Flood J, Seaworth B, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis. 2014;20:812–21.
15. World Health Organization (WHO). Global tuberculosis report 2015. Geneva: WHO Press, 2015. WHO/HTM/TB/2015.22. Available at: http://www.who.int/tb/publications/global_report/en/
16. Zhao YL, Xu SF, Wang LX, et al. National Survey of Drug-Resistant Tuberculosis in China. N Engl J Med. 2012;366:261–70.
17. Shi D, Li H, Zhao Y, et al. Extensively Drug-Resistant Tuberculosis, Central China, 2007–2009. Emerg Infect Dis. 2012;18:1904–5.
18. Tang S, Tan S, Yao L, et al. Risk Factors for Poor Treatment Outcomes in Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation. PLoS One. 2013;8:e82943.
19. Tang S, Zhang Q, Yu J, et al. Extensively Drug-Resistant Tuberculosis, China. Emerg Infect Dis. 2011;17:558–60.
20. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis (fourth edition). Geneva: WHO, 2009.
21. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640–5.
22. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640–5.
23. Sun Z, Zhao Y, Zhang X, et al. Characterization of extensively drug-resistant mycobacterium tuberculosis clinical isolates in China. J Clin Microbiol. 2008;46:4075–7.
24. Qi YC, Ma MJ, Li DJ, et al. Multidrug-resistant and extensively drug-resistant tuberculosis in multi-ethnic region, Xinjiang Uygur Autonomous Region, China. PLoS One. 2012;7:e32103.
25. National Technical Steering Group of the Epidemiological Sampling Survey for Tuberculosis, Implementing Office of the Epidemiological Sampling Survey for Tuberculosis. The prevalence of pulmonary tuberculosis in a national survey across China in 2010. Zhong Hua Jie He He Xi Za Zhi. 2012;35:665–8.

26. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008;178:1075–82. doi:10.1164/rccm.200801-1320OC.

27. Leimane V, Dravniec G, Rekstina V, Sture I, Kammerer S, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004. Eur Respir J. 2010;36(3):584–93. doi:10.1183/09031936.0003710.

28. Liu CH, Li L, Chen Z, Wang Q, Hu YL, et al. Characteristics and Treatment Outcomes of Patients with MDR and XDR Tuberculosis in a TB Referral Hospital in Beijing: A 13-Year Experience. PLoS One. 2011;6:e19399. doi:10.1371/journal.pone.0019399.

29. Kliman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J. 2009;33:1085–94. doi:10.1183/09031936.00155708.

30. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181:80–6.

31. Zhong NS, Wang C, Yao WC, Chen P, Kang J, Huang SG, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176:753–60.

32. Inghammar M, Ekbom A, Engström G, Ljungberg B, Romanus V, Lofdahl CG, et al. COPD and the risk of tuberculosis: A population-based cohort study. PLoS One. 2010;5:e10138.

33. Kim JH, Park JS, Kim KH, Jeong HC, Kim EK, Lee JH. Inhaled corticosteroid is associated with an increased risk of tuberculosis in patients with chronic obstructive pulmonary disease. Chest. 2013;143:1018–24.

34. Limó LDC, Mustafal AR, Yunus F, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. Asia Pac Fam Med. 2015;14:4.

35. Gaude GS, Rajesh BP, Chaudhury A, et al. Outcomes associated with acute exacerbations of chronic obstructive pulmonary disorder requiring hospitalization. Lung India. 2015;32:465–72.

36. World Health Organisation. Chronic respiratory diseases, burden of chronic obstructive pulmonary disease. 2015: Available at: http://www.who.int/respiratory/copd/burden/en/. Accessed 27 July 2015.

37. Hasegawa W, Yamauchi Y, Yasunaga H, et al. Factors affecting mortality following emergency admission for chronic obstructive pulmonary disease. BMC Pulm Med. 2014;14:151.

38. Sapere E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61:250–8.

39. Liu CH, Yang N, Wang Q, Hu YL, Li L, Zhang GY, et al. Risk factors associated with fluoroquinolone resistant tuberculosis in a Beijing tuberculosis referral hospital. Respir Med. 2011;105:918–25.